Entrada Therapeutics, Inc. (TRDA) Financial Statements
Entrada Therapeutics, Inc. (TRDA) reported trailing twelve-month revenue of $4.7M (down 94.1% year on year) and net income of -$165.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$134.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TRDAEntrada Therapeutics, Inc.Follow TRDA — free
—
Price chart with a free account
- Market cap
- 171.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 129.0 | 210.8 | 25.4 | 4.7 | |
| Research & development | 99.9 | 125.3 | 142.3 | 140.7 | |
| Operating income | -3.2 | 47.0 | -157.9 | -176.5 | |
| Pre-tax income | 12.1 | 66.5 | -142.8 | -165.0 | |
| Income tax | 18.7 | 0.9 | 0.9 | 0.8 | |
| Net income | -6.7 | 65.6 | -143.8 | -165.8 | |
| Diluted EPS ($) | -0.20 | 1.68 | -3.47 | -3.96 | |
| Diluted shares (mn) | 33.1 | 39.0 | 41.4 | — |
USD millions · SEC XBRL
Entrada Therapeutics, Inc. — questions
- What is Entrada Therapeutics, Inc.'s revenue?
- $4.7M over the twelve months to 2026-06-30, down 94.1% year on year, from its 10-Q and 10-K filings.
- What is Entrada Therapeutics, Inc.'s net income?
- -$165.8M over the twelve months to 2026-06-30.
- What is Entrada Therapeutics, Inc.'s free cash flow?
- -$134.4M over the twelve months to 2026-06-30.
- What are Entrada Therapeutics, Inc.'s diluted earnings per share?
- $-3.96 over the twelve months to 2026-06-30.
Every figure on this page comes from Entrada Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.